secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0001104659-23-126021
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute completes Phase 2 DME enrollment, initiates Phase 3 for congenital hyperinsulinism
--------------------------------------------------------------------------------

- Phase 2 study of oral RZ402 for diabetic macular edema enrolled ~95 participants; topline data expected mid-Q2 2024.
- Phase 3 sunRIZE study of RZ358 for congenital hyperinsulinism initiated; first clinical site activated outside US.
- Phase 3 to enroll up to 56 patients at ~20 centers in >12 countries; topline results anticipated mid-2025.
- RZ358 previously received EMA PRIME designation in October 2023 for congenital hyperinsulinism.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465923126021/0001104659-23-126021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465923126021/tm2332663d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-126021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer